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Summary. The development of neutralizing antibodies
to factor VIII (FVIII) is the most serious complication
of therapy for haemophilia A. There is now excellent
documentation that a large number of both genetic
and environmental factors contribute to the risk of
FVIII inhibitor incidence. One of the environmental
factors that has been proposed as an influence on this
complication is the occurrence of FVIII product
switching. There are only a small number of clinical
studies that have addressed this question, and thus,
the amount of objective information available to
assess this association is limited. In this review, in
addition to summarizing past evidence pertinent to
this subject, we present the results of a
complementary strategy, a Delphi analysis, to add to
the considerations of product switching and FVIII
immunogenicity. With the imminent arrival in the
clinic of several new FVIII products, the haemophilia
community must be prepared to collect prospectively
controlled data to better address this important
management issue.
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Introduction
Current protein replacement therapies for haemophilia
are well documented to be haemostatically effective
and safe [1]. Since the catastrophic events of the mid-
1980s, the risk of infectious agent transmission has
become essentially theoretical, thus leaving the inher-
ent immunogenicity of the clotting factor concentrates
as the principal treatment-related complication of hae-
mophilia therapy. This is a particular concern in hae-
mophilia A [2].
The pathogenesis and biology of the factor VIII
(FVIII) immune response has been a subject of extensive
investigation for the past three decades, and some facts
are now well established. The cumulative incidence of
functionally neutralizing FVIII antibodies (FVIII inhibi-
tors) in previously untreated patients (PUPs) is approxi-
mately 30% and these antibodies usually develop
during the first 10–20 exposures to FVIII exposure [3].
In contrast, in patients who have been repeatedly trea-
ted with FVIII concentrates (>150 exposures–previously
treated patients [PTPs]), the baseline inhibitor risk is
approximately 2–3 per 1000 patient-years [4–6].
It is now well recognized that the risk of inhibitor
development in PUPs is determined by a complex
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interaction between multiple genetic and environmen-
tal factors [7]. Among the genetic risk factors, the
FVIII mutant genotype, ethnicity, and variants of sev-
eral immunoregulatory genes have all been character-
ized to play a role as determinants of the inhibitor
risk. Similarly, in terms of environmental risk determi-
nants, the presence of intercurrent inflammation,
intensity of treatment, surgery, the age of first FVIII
exposure, FVIII dose and FVIII product type have all
been evaluated as potential risk modifiers and have
been found to contribute variably to this outcome.
In light of the significantly higher incidence of inhib-
itor development in PUPs, most of the studies address-
ing risk factors for FVIII immunogenicity have been
conducted in this population, and not in PTPs. Never-
theless, the incidence of inhibitors does not disappear
over the lifetime of the person with haemophilia
(PWH) and there is recent evidence that in elderly
PTPs there is a slight resurgence of this risk [8]. An
examination of data relating to the baseline risk of
inhibitors in PTPs shows that recent studies have doc-
umented a threefold increase in incidence (1.5–5.3
per/1000 patient-years). The cause of this observation
remains unknown, but may be due to an increased
awareness of inhibitors in this population and an
increased testing frequency.
One of the factors that may influence inhibitor devel-
opment in PTPs is the introduction of new FVIII con-
centrates. The role of product switching as a risk
factor for FVIII immunogenicity has attracted attention
in several studies in the past, and now with the intro-
duction of several new FVIII products into the clinic
over the next 5 years will again generate discussion.
Immunological Considerations of FVIII Product
Switching
Assessing the risk of eliciting an immune response to
FVIII when a new concentrate is introduced for a pre-
viously treated patient poses a number of interesting
questions.
Patients with severe FVIII deficiency lack the capac-
ity to eliminate high-affinity CD4+ T cells by induc-
tion of apoptosis in the thymus and, by the same
token, lack the capability of generating natural
Foxp3+ T regulatory cells to FVIII (although mecha-
nisms of peripheral tolerance induction are intact).
This scenario creates conditions under which any
FVIII presenting even small structural alterations (to
the primary amino acid sequence or to posttransla-
tional modifications) is at risk of eliciting an immune
response. These variances in structure can generate
new B cell epitopes as well as new T-cell epitopes.
An important immunological attribute of FVIII is its
potential for activating the innate immune system.
Innate responses are not associated with immunologi-
cal memory and thus, whatever the result of previous
exposures to FVIII, each new administration is a new
challenge to the innate immune system and carries a
risk of eliciting an immune response. This may be all
the more critical because the germinal configuration B
cell repertoire contains cells that are capable of recog-
nizing FVIII.
Algorithms are available to predict whether either
new B or T-cell epitopes have been generated, with a
predictive value as high as 80%, when several of those
algorithms are combined. In addition, a number of in
vitro assays can be performed to determine whether
potential new epitopes are present and of clinical rele-
vance. Nevertheless, these types of analysis have not
achieved widespread clinical application.
Prior Experiences of FVIII Immunogenicity with
Product Switching
The potential for enhanced FVIII immunogenicity fol-
lowing product switching has been recognized for
some time, and while the diversity of concentrates has
increased over time, and will further expand over the
next 5 years, the initial evidence that this phenomenon
could occur concerns two inhibitor “outbreaks”
20 years ago in Belgium and the Netherlands involv-
ing a switch of plasma-derived concentrates [9,10]. In
these two studies, a significant excess of inhibitors
was documented in two cohorts of PTPs (up to five-
fold increase; 20 per 1000 patient-years) with the
introduction of plasma-derived FVIII (pd-FVIII) prod-
ucts that had undergone novel viral inactivation pro-
cesses. It is assumed that these inactivation processes
(long-duration pasteurization) resulted in structural
changes to FVIII that initiated the subsequent immune
responses. In contrast, all subsequent studies of FVIII
product switching have not shown any evidence of
enhanced immunogenicity (see Table 1).
Two Canadian studies have evaluated switches from
pd-FVIII to recombinant FVIII (rFVIII) [11], and a
later switch from first to second generation rFVIII in a
total of >700 patients for up to 2 years [12]. Neither
of these studies documented an increase in inhibitor
incidence, and where new inhibitors were found they
were always transient. In addition, these studies found
evidence of pre-switch low titre inhibitors that had
not been diagnosed at the treating clinic sites, high-
lighting one of the complicating issues in the interpre-
tation of inhibitor test results around the time of
product switching.
In the UK, a small study of 26 PTPs switching from
intermediate to high purity pd-FVIII showed no
increase in inhibitor risk [13] and another study of 33
PTPs switching from full-length FVIII to recombinant
B-domain deleted FVIII showed just a single low titre
inhibitor [14].
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Two Irish studies, one evaluating inhibitors at the
time of a switch from Chinese hamster ovary (ReFac-
to) to baby hamster kidney cell-derived (Kogenate)
rFVIII (94 patients) [15] and the second, assessing the
switch to a third generation full-length rFVIII (Ad-
vate) in 113 patients both failed to show an excess
of new inhibitors [16].
In the retrospective collection of inhibitor data in the
CANAL study, 104 patients switched their FVIII product
after a median of five exposures (range 2–48 exposures)
[17]. The follow-up of this group showed a relative risk
for inhibitor development of 0.9 (CI 0.6–1.6).
Most recently, as part of the RODIN study, 20
patients switched from a pd-FVIII product to rFVIII
after a median of four exposure days and again the
adjusted hazard ratio (HR) of 1.05 (confidence inter-
val [CI] 0.44–2.49) indicated no evidence of increased
inhibitor risk [18]. In this same study, 94 patients
used multiple FVIII product brands. Seventy-one
patients switched products once, 13 twice and 10
patients more often. Switching between different FVIII
brands showed no enhanced risk of inhibitors (HR
0.99, CI 0.63–1.56).
Studies are ongoing in the UK and Australia follow-
ing large scale switches from full-length rFVIII to a
third generation B-domain deleted product. Prelimin-
ary results from these studies have shown no increased
incidence of inhibitors following switching.
Strategies for Evaluating the Risk of FVIII
Immunogenicity Associated with Product Switching
The currently available studies addressing this subject
represent a mixture of methodological approaches.
Several of the studies are retrospective in nature and
thus prone to recall bias, and some of the studies are
missing appropriate control groups. Overall, the
amount and quality of data relating to the issue of
FVIII immunogenicity associated with product switch-
ing is modest.
In the text below, we have approached this question
with an alternative methodology, using a modified
Delphi technique. This process can be summarized as
a structured group communication in which a com-
plex problem (in this case, the risk of FVIII immuno-
genicity associated with product switching) can benefit
from the subjective judgements of a number of
experts. The process often, as in this case, begins with
a face-to-face meeting to set the context of the com-
munication and then proceeds through several rounds
of questions and independent responses from the indi-
vidual members of the expert group.
We believe that in the case of this subject matter,
where the presence of high quality objective data is
limited, that a Delphi approach adds useful additional
information to the existing literature.
Materials and methods
A modified Delphi consensus process was used to
reach the consensus statements presented in the fol-
lowing manuscript. An initial in person full day work-
shop was held in Toronto in September 2011. At this
face-to-face meeting, each of the authors reviewed the
available evidence on specific topics related to product
switching and a series of presentations were given, fol-
lowed by a general discussion. No recommendations
were discussed during the meeting. After the meeting,
two sequential Delphi rounds were performed. All of
the authors, except Davide Matino, participated in the
original face-to-face meeting and all rounds of the Del-
phi process. Mr. Matino was responsible for the analy-
sis of the Delphi responses. The 12 expert panellists
responded through an ad hoc web-based platform, and
they were at all times blinded to individual votes from
their colleagues. After each iteration of the Delphi sur-
vey, the panellists were presented with mean scores
produced by the group. The first round of analysis
aimed at identifying and ranking the items to be used
as headings to organize the statements in the consensus
paper. Ten items were initially proposed, asking the
panellists to rank them in order of relevance. The 12
panellists were also asked to propose modifications of
existing items, or to suggest the deletion of items or
addition of new statements. After 3 iterations, an
ordered list of 14 items was agreed upon, with consen-
sus over 75% about both the wording and the ranking
of the items. In the second round of the analysis, we
proposed three statements for each of the 14 items and
asked the panellists to score these statements. The pan-
ellists were asked to state for each statement their will-
ingness to include or exclude the statement, and they
were also prompted to propose modifications of exist-
ing statements or the addition of new ones. At each
iteration, only items that were scored as “should
Table 1. Summary of clinical studies addressing the incidence of FVIII











Baglin et al. [13] 26 0
Singleton et al. [15] 94 (<20 months) 0.042
Gouw et al. [17] 104 (>50 exposure days) 0




Rea et al. [14] 33 (> 3 months) 0.033
Siegmund et al. [23] 118 0
Bacon et al. [16] 113 (>100 exposure days) 0.009
Gouw et al. [18] 20 (pd-FVIII to rFVIII)





CI, confidence interval; FVIII, factor VIII; HR, hazard ratio; pd-FVIII,
plasma-derived factor VIII; rFVIII, recombinant factor VIII.
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include” by over 50% of panellists were proposed in
subsequent rounds of the process. After 3 iterations,
the scores became stable, and only the statements
scored as “should include” by more than 60% of pan-
ellists have been kept in the final document.
Statements are reported for each item ordered by
the descending level of consensus reached in the final
iteration (consensus scores indicated in brackets).
Results
Consensus items and statements
Item 1. Evidence documenting an increased risk of
FVIII inhibitor development with product switching is
weak. A. The most direct evidence we have about the
risk of inhibitor development after recombinant prod-
uct switching consists of reports from Canada, UK
and Ireland. From these studies, there is no clear sig-
nal of an increase in inhibitor development when
switching to and from the currently available recombi-
nant factor concentrates (90%).
B. Some of the reluctance to change the type of con-
centrate that PWH are using has its origins in the past
epidemics of blood-borne infections. In addition, inhib-
itor formation was observed following the introduction
of two specific plasma-derived-FVIII concentrates in
the 1990s. Little if any evidence points to an increased
risk of inhibitor development with switching between
different recombinant FVIII products. After products
became safer, the frequency of real-world switching is
much higher than actually appreciated (66%).
Item 2. The risk of inhibitor development is likely to
be less with FIX product switches compared to FVIII
switches. A. The evidence about side effects of FIX
treatment, with either plasma-derived or recombinant
FIX, indicates an overall low risk of inhibitors. There
is no evidence of an increased rate of inhibitors linked
to switching (100%).
B. Data about product switching in haemophilia B
patients are far rarer than for haemophilia A, due to
the lower prevalence of the disease, lower incidence of
inhibitors, and less availability of other concentrates
to switch to and from (83%).
C. The risk of inhibitors after switching from one
brand of FIX to another is mostly unknown, but it is
likely to be proportional to the overall risk of inhibi-
tors to FIX, which is substantially lower than for
FVIII (75%).
Item 3. FVIII inhibitor development is more likely
when product switches occur during the first 50 expo-
sure days. A. In the absence of robust evidence about
switching during the period of tolerization, it is con-
sidered beneficial, whenever possible, to keep patients
on the same product for the first 50 ED. On the other
hand, should the reason for switching be an important
one, it has to be considered that no evidence exists
against switching during this time (92%).
B. We did not find any high quality evidence
addressing this point. The CANAL study did not find
any effect of switching on the rate of inhibitors in
PUPs (76%).
Item 4. The risk of FVIII inhibitor development may
be increased with the new FVIII conjugates and fusion
proteins. A. In theory, any change to the native FVIII
protein could initiate an increase in immunogenicity.
Careful observation for inhibitors will be required
when introducing the new FVIII molecules (92%)
B. No evidence is currently available in human
beings about the immunogenic potential of these novel
FVIII products. PEGylation, other forms of conjuga-
tion and fusion proteins have been used previously in
humans without strong immune responses. All of these
modifications could theoretically increase or reduce
immunogenicity, and the new molecules have to be
tested clinically to answer this question (75%).
C. Bioengineering factor VIII could either enhance
or reduce the immunogenicity of the protein (69%).
Item 5. The risk of an inhibitor after switching may
be different for severe vs. moderate or mild haemo-
philia. A. Mild or moderate haemophilia patients are
usually not on prophylaxis, and in most cases the
development of an inhibitor is associated with events
triggering the use of high doses of factor (e.g. trauma
or surgery); in these situations, the risk attributable to
a product switch will be difficult to assess (85%).
B. Mild and moderate haemophiliacs have a signifi-
cantly lower risk of inhibitor development. Despite
the known importance of the type of gene mutation in
the inhibitor risk in this group of patients, the mecha-
nisms by which they develop inhibitors is not fully
characterized, so that surveillance is warranted after
product switching (77%).
C. Mild and moderate haemophiliacs have a signifi-
cantly lower risk of inhibitor development, because
they are tolerized by their own FVIII. The mechanisms
by which this group of patients develop inhibitors are
not well characterized, so that surveillance is war-
ranted after product switching (75%).
Item 6. The risk of FVIII inhibitor development with
product switching is increased in patients with a past
history of an inhibitor. A. The evidence for inhibitor
development with product switching in patients with a
past history of an inhibitor is weak and controversial.
It is theoretically possible that changing the therapeu-
tic molecule could break the tolerance to FVIII, but
conversely we have anecdotal evidence of successful
immune tolerance induction with a molecule different
from that inducing the inhibitor (77%).
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B. The evidence for inhibitor development with
product switching in patients with a past history of an
inhibitor is weak and controversial. It is theoretically
possible that changing the therapeutic molecule could
break the tolerance to FVIII, but conversely we have
anecdotal evidence of successful immune tolerance
induction with a molecule different from that inducing
the inhibitor. We have also evidence of patients
switched after success of immune tolerance, without
relapse after switching (69%).
C. Product registration studies usually exclude
patients with a past personal history of inhibitors. A
handful of cases of such patients have been switched
in tender-related en masse switching exercises without
any evidence of new high responding inhibitor forma-
tion (67%).
D. There is no strong evidence for this statement.
However, whenever a product switch is needed, strict
surveillance is warranted (61%).
Item 7. There may be an increased risk of inhibitor
development when switching product just prior to sur-
gery or intensive treatment. A. Even if not formally
estimated in a rigorous way, the risk of inhibitors
appears to be high after surgery and/or intensive treat-
ment. There is no evidence relating to the contributory
role of concomitantly switching FVIII (84%).
B. Surgery and/or intensive FVIII treatment appears
to be potent trigger to inhibitor formation. Whether a
concomitant switch of product enhances the likelihood
of inhibitor development in this setting remains
unclear and will be difficult to evaluate (84%).
Item 8. The risk of a FVIII inhibitor development
increases with the frequency of product switching. A.
The haemophilia population in countries where the
supply of factor concentrates is determined by a ten-
der system has undergone several switches. The mea-
sured increase in the inhibitor incidence, if any, lies in
the order of <3–5 in 1000 (84%).
B. There is no direct evidence to substantiate this
statement, and information about the frequency of
switching has never been systematically collected. The
overall risk of inhibitor development after switching is
very low and it is very unlikely that the risk can incor-
porate a clinically significant gradient associated with
the number of previous switches (77%).
Item 9. There is an increased risk of FVIII inhibitor
development when switching concentrates in patients
being treated on demand as opposed to prophylacti-
cally. A. The effect of treatment regimen on inhibitor
development is controversial in PUPs and largely
unknown in PTPs. There is no evidence to support or
deny this statement (85%).
B. There is no evidence to support this statement
(77%).
Item 10. There is an increased risk of FVIII inhibitor
development when switching between plasma-derived
and recombinant FVIII concentrates. A. There is no
evidence to support this statement. The Canadian sur-
veillance of product switching for the entire population
to recombinant FVIII in 1988 did not show any increase
in the baseline risk for inhibitor development (92%).
B. There is no evidence that the risk of inhibitor
development associated with switching from any
plasma-derived concentrate to any recombinant prod-
uct is different from that associated with switching
between two different plasma-derived or two recombi-
nant factor concentrates (77%).
Item 11. There is an increased risk of FVIII inhibitor
development when switching between B-domain
deleted and full-length FVIII concentrates. A. The
preliminary analysis of the prospective parallel obser-
vation of patients who switched or did not switch
between these products in the UK population has not
shown an increase in the inhibitor rate after switching
to B-domain deleted FVIII (92%).
B. The proper experiment to answer this question
would be a crossover study, with PUPs randomized to
one or the other molecule and then switched over
when PTPs. Evidence from case series is likely to be
biased and inconclusive (83%).
C. There is no high level evidence to support this
statement. A recent meta-analysis of observational tri-
als suggests a difference, but several methodological
and design flaws make the results of this study likely
to be biased (77%).
Item 12. FVIII inhibitor risk associated with recombi-
nant FVIII use could be influenced by the type of cell
employed for FVIII production. A. There is no
evidence to support the statement. If any risk exists,
this risk is low enough to be incorporated in the <1
per 1000 inhibitors observed in PTP populations
(85%).
B. The hypothesis is theoretically plausible; the type
of cell used to produce recombinant FVIII influences
the final structure of the molecule, for example, its
degree and nature of glycosylation. We currently have
no evidence to support or deny this statement (77%).
Item 13. All recombinant FVIII products have the
same risk of inhibitor development. A. Preliminary
analysis of the EUHASS data shows a substantial
equivalence of the risk of inhibitors in PUPs treated
with any of the recombinant molecules. Most of the
remaining evidence is made by uncontrolled case series
not allowing any reliable comparison (82%).
B. There is no evidence demonstrating a difference
in immunogenicity between recombinant FVIII prod-
ucts (all registration trials show the same low inhibi-
tor rate for all the currently available molecules).
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Robust evidence from prospective parallel observation
does not yet exist (77%).
C. The use of an antigenically modified plasma-
derived molecule in 1993 in the Netherlands and Bel-
gium was easily recognized to be associated with an
increased risk for transient inhibitors. Until proven
false, all the available recombinant molecules can be
considered immunologically equivalent (67%).
D. Nevertheless, differences in cell lines, carbohy-
drate modifications, and manufacturing processes can-
not a priori be assumed to be equivalent in their
immunogenicity before clinical trials are performed.
The example of the increased immunogenicity of a
structurally identical recombinant erythropoietin
placed in a new vial design is an important reminder
of this fact (62%).
Item 14. The risk of FVIII inhibitor development with
product switches can be predicted by genetic analy-
sis. A. It is likely that mild haemophiliacs with dys-
functional FVIII molecules can be tolerant to their
own FVIII but these patients may be prone to develop
inhibitors to native (either recombinant or plasma-
derived) FVIII protein administered for treatment.
Genetic analysis may help identify this subgroup
(92%).
B. There is accumulating evidence that genetic
analysis can predict the risk of inhibitor development
in PUPs. How much this genetic evidence is relevant
for predicting inhibitor risk in PTPs is largely
unknown (92%).
Summary Statement and Future Studies
The outcome of the Delphi process detailed above
represents a complementary approach to providing
information relating to the risk of FVIII inhibitor
development associated with product switching. This
information is not intended to supersede previous clin-
ical data published on this subject, nor is it meant to
diminish the value of ongoing prospective studies of
this phenomenon. It is also important to recognize
that the issue of FVIII immunogenicity is undergoing
continual re-examination, and that while this Delphi
process occurred at a specific point in time, there has
been additional information published since comple-
tion of the Delphi review that merits consideration
[18]. In this Delphi process, a mean consensus score
of 80% was reached for the 36 statements reviewed.
There are currently a number of novel rFVIII con-
centrates that are undergoing late phase clinical trials,
and several of these products will likely be licensed
for more widespread clinical application in the next
2–3 years. All of these rFVIII proteins are modified in
some aspect of their structure, as novel B-domain
truncated molecules [19], as FVIII conjugates [20] or
as fusion proteins [21]. There is evidence that all of
these products provide some biological enhancement
over native FVIII, most often some degree of prolon-
gation of the FVIII half-life.
Clinicians treating PWH will need to consider the
role of these new FVIII products for the management
of their patient groups, and it is quite likely that deci-
sions concerning product introduction will be highly
variable based upon a variety of factors including
geography, patient age, current product satisfaction
and treatment regimen and cost. Potential product
immunogenicity will also be a key consideration in the
evaluation of these new treatments and prospective
evaluation of this complication must be incorporated
into future clinical practice.
As the haemophilia community moves forward, it is
critical that more detailed information be gathered
relating to FVIII product immunogenicity and the
influence of product switching. Both switching and
non-switching PWH should be prospectively enrolled
in registries evaluating inhibitor incidence and inhibi-
tor tests should be performed as a minimum, immedi-
ately prior to any product switch and for 2–3 months
post switching. Examples of successful multinational
registries documenting the incidence of adverse treat-
ment outcomes are already in existence [22]. The
organization of prospective, appropriately controlled
surveillance programmes is a key element in the
attainment of objectively useful information concern-
ing this treatment complication.
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